ReviewLe infezioni in medicina2023
Review in Le infezioni in medicina, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 25 citations in OpenAlex.
- Species-Dependent Antifungal Profiles of Chitosan and Sulphated Polysaccharide-Rich Extract fromMarine drugs · 2026Article
- Fluconazole Disk Diffusion on CHROMagar Candida Plus for Differentiation BetweenJournal of fungi (Basel, Switzerland) · 2026Article
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Clinical implications in patients with isolation of Candidozyma auris in a single tertiary hospital.BMC infectious diseases · 2026Article
- Clinical characteristics, healthcare-associated exposures, and antifungal susceptibility patterns of Candida auris colonization and invasive infections: a retrospective observational study at a single center in Turkey.BMC infectious diseases · 2026Observational
- Caspofungin Reshapes the Extracellular Vesicles Metabolome ofJournal of fungi (Basel, Switzerland) · 2026Article
- EditingBiomolecules · 2026Review
- Bioactive glass S53P4 cream kills ESKAPE panel multidrug resistant pathogens andFrontiers in pharmacology · 2026Article
- Minimum Inhibitory Concentrations of Anidulafungin as a Potential Predictor of Biocide Susceptibility of Clade 1 Candidozyma (Candida) auris Isolates.MicrobiologyOpen · 2025Article
- Biocide, antifungal susceptibility and virulence characteristics of Clade 1 Candidozyma auris strains.Annals of clinical microbiology and antimicrobials · 2025Article
- Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.Infectious disease reports · 2025Review
- Protease production by Serratia liquefaciens NRC1 using fish gut waste as a sustainable approach to antimicrobial peptide generation and combating Candida auris acquired resistance.Microbial cell factories · 2025Article
- EnhancingMicrobiology spectrum · 2025Article
- The Impact of Epidemiological Trends and Guideline Adherence on Candidemia-Associated Mortality: A 14-Year Study in Northeastern Italy.Journal of fungi (Basel, Switzerland) · 2025Article
- Nanoparticles in the battle against Candida auris biofilms: current advances and future prospects.Drug delivery and translational research · 2025Review
- Multidrug-ResistantThe Malaysian journal of medical sciences : MJMS · 2025Review
- Article
- Ellagic Acid Potentiates the Inhibitory Effects of Fluconazole AgainstAntibiotics (Basel, Switzerland) · 2024Article
- Variable sensitivity of clinical Candida auris strains to Biocides: implications for infection control in Healthcare Settings.BMC microbiology · 2024Article
- IdentifyingJournal of clinical microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.